tiprankstipranks
Trending News
More News >
Healios KK (JP:4593)
:4593
Japanese Market
Advertisement

Healios KK (4593) AI Stock Analysis

Compare
2 Followers

Top Page

JP:4593

Healios KK

(4593)

Rating:41Neutral
Price Target:
¥494.00
▼(-9.02% Downside)
Healios KK's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and high leverage. Technical analysis indicates bearish momentum, and the negative P/E ratio reflects valuation challenges. The absence of earnings call data and corporate events means these factors do not influence the score.

Healios KK (4593) vs. iShares MSCI Japan ETF (EWJ)

Healios KK Business Overview & Revenue Model

Company DescriptionHealios KK (4593) is a pioneering biotechnology company based in Japan, focusing on the development of regenerative medicine and cell therapy products. The company primarily operates in the healthcare sector, leveraging advanced technologies to develop innovative treatments aimed at addressing unmet medical needs. Its core products are based on induced pluripotent stem cells (iPSCs), which have the potential to transform into various cell types, making them highly versatile for therapeutic applications. Healios KK is committed to advancing therapies that can significantly improve patient outcomes in areas such as ophthalmology and immunology.
How the Company Makes MoneyHealios KK generates revenue through the development and commercialization of its regenerative medicine and cell therapy products. The company collaborates with research institutions and pharmaceutical companies to advance its product pipeline, which includes therapies targeting retinal diseases and acute respiratory distress syndrome. Key revenue streams include licensing agreements, research and development collaborations, and potential sales of its proprietary cell-based therapies upon regulatory approval. Strategic partnerships and collaborations help the company to share the cost of development and access broader markets, thereby contributing to its earnings.

Healios KK Financial Statement Overview

Summary
Healios KK is facing significant financial difficulties, with declining revenues, substantial losses, and high leverage. The income statement, balance sheet, and cash flow analysis all indicate poor financial health, with negative profitability metrics and high financial risk.
Income Statement
20
Very Negative
Healios KK's income statement reveals significant challenges. The company has experienced a dramatic decline in revenue, with a negative growth rate of 80.95% in the TTM period. Profitability metrics are concerning, with negative net profit margins and EBIT margins indicating substantial losses. The gross profit margin has also deteriorated, reflecting operational inefficiencies.
Balance Sheet
30
Negative
The balance sheet shows a high debt-to-equity ratio, suggesting significant leverage and potential financial risk. Return on equity is negative, indicating that the company is not generating returns for shareholders. The equity ratio is relatively low, which may impact financial stability.
Cash Flow
25
Negative
Cash flow analysis highlights ongoing cash flow challenges, with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is not sufficient to cover net losses. The company has shown some improvement in free cash flow growth, but overall cash flow health remains weak.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue112.00M560.00M121.00M90.00M41.00M27.00M
Gross Profit-180.00M432.00M108.00M90.00M41.00M27.00M
EBITDA-2.30B-2.54B-3.16B-4.52B-3.61B-3.97B
Net Income-5.99B-4.24B-3.82B-5.17B-4.91B-5.51B
Balance Sheet
Total Assets16.84B14.19B15.15B15.03B23.97B23.17B
Cash, Cash Equivalents and Short-Term Investments6.25B3.67B6.72B7.25B15.13B13.92B
Total Debt2.60B2.66B4.53B7.15B11.96B11.40B
Total Liabilities15.56B12.11B11.29B10.65B15.33B15.32B
Stockholders Equity1.25B2.06B3.86B4.38B8.64B7.84B
Cash Flow
Free Cash Flow-2.32B-1.83B-2.85B-4.86B-5.39B-4.26B
Operating Cash Flow-2.30B-1.82B-2.82B-4.60B-5.09B-3.94B
Investing Cash Flow-1.54B-1.42B-1.12B-909.00M-736.00M-1.22B
Financing Cash Flow1.32B77.00M3.34B-2.50B6.99B803.00M

Healios KK Technical Analysis

Technical Analysis Sentiment
Positive
Last Price543.00
Price Trends
50DMA
562.74
Negative
100DMA
470.26
Positive
200DMA
355.91
Positive
Market Momentum
MACD
-15.87
Positive
RSI
48.14
Neutral
STOCH
60.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4593, the sentiment is Positive. The current price of 543 is below the 20-day moving average (MA) of 551.55, below the 50-day MA of 562.74, and above the 200-day MA of 355.91, indicating a neutral trend. The MACD of -15.87 indicates Positive momentum. The RSI at 48.14 is Neutral, neither overbought nor oversold. The STOCH value of 60.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4593.

Healios KK Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
¥20.22B
6.33%-250.29%
52
Neutral
¥17.37B
-22.81%2.69%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
49
Neutral
¥17.82B206.40
13.83%34.66%
47
Neutral
¥19.32B
8.47%
41
Neutral
¥59.79B
-78.54%10.23%
33
Underperform
¥57.00B
1242.62%2.56%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4593
Healios KK
543.00
329.00
153.74%
JP:4599
StemRIM Inc.
313.00
-100.00
-24.21%
JP:4894
Cuorips Inc.
7,250.00
-290.00
-3.85%
JP:4978
ReproCELL Inc.
196.00
67.00
51.94%
JP:7774
Japan Tissue Engineering Co., Ltd.
502.00
-25.00
-4.74%
JP:7776
CellSeed Inc.
504.00
-383.00
-43.18%

Healios KK Corporate Events

Healios Secures Patent Approval for Universal Donor Cells in Japan
Aug 15, 2025

Healios K.K. announced the approval of a patent for its Universal Donor Cells (UDCs) by the Japan Patent Office, marking a significant milestone in the company’s innovation in regenerative medicine. The UDC technology, which reduces immune rejection risks, enhances Healios’ competitive edge globally and positions its UDCs as a potential industry standard, facilitating joint research and licensing agreements worldwide.

The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.

Healios K.K. Secures JPY 7 Billion Subsidy for CDMO Business Expansion
Jul 16, 2025

Healios K.K. has been selected for a JPY 7 billion subsidy under Japan’s METI program to support capital investment in regenerative, cell, and gene therapy manufacturing facilities. This funding will enable Healios to expand its CDMO business, enhancing its competitive edge in the global market by integrating advanced technologies and establishing a robust international platform. The initiative aligns with Japan’s industrial policy and aims to strengthen Healios’s position as a leader in regenerative medicine, fostering new partnerships and enhancing shareholder value.

The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025